Trial Profile

A 96-Week, Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of EPZICOM Versus TRUVADA Administered in Combination With KALETRA in Antiretroviral-Naive HIV-1 Infected Subjects.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 04 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lamivudine/abacavir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Lopinavir/ritonavir
Indications HIV-1 infections
Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
Acronyms HEAT
Sponsors GSK

31 Jul 2009 Results published in AIDS.
10 Feb 2009 Results presented at CROI 2009.
07 Aug 2008 96-Week results show comparable efficacy and tolerability between the two treatment arms, with data presented at the 17th International AIDS Conference [sourced from a GlaxoSmithKline media release].

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com